PD 142893
| Code | Size | Price |
|---|
| TAR-T25922-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
PD 142893 is a functional endothelin-stimulated vasoconstriction antagonist.
CAS:
143037-36-9
Formula:
C50H65N7O10
Molecular Weight:
924.109
Purity:
0.98
SMILES:
CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(C)=O)[C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O
References
1. Zimmermann M, Vatter H, Weyrauch E, Lange BN, Krishnan R, Raabe A, Seifert V. Characterization of the potent combined endothelin(A/B)-antagonist PD 142893 on cerebral vessels. Neurol Res. 2004 Sep;26(6):692-7. PubMed PMID: 15327761.
2. Warner TD, Allcock GH, Mickley EJ, Corder R, Vane JR. Comparative studies with the endothelin receptor antagonists BQ-123 and PD 142893 indicate at least three endothelin receptors. J Cardiovasc Pharmacol. 1993;22 Suppl 8:S117-20. PubMed PMID: 7509920.
3. Schroeder RL, Keiser JA, Cheng XM, Haleen SJ. PD 142893, SB 209670, and BQ 788 selectively antagonize vascular endothelial versus vascular smooth muscle ET(B)-receptor activity in the rat. J Cardiovasc Pharmacol. 1998 Dec;32(6):935-43. PubMed PMID: 9869499.
4. Warner TD, Allcock GH, Corder R, Vane JR. Use of the endothelin antagonists BQ-123 and PD 142893 to reveal three endothelin receptors mediating smooth muscle contraction and the release of EDRF. Br J Pharmacol. 1993 Oct;110(2):777-82. PubMed PMID: 8242251; PubMed Central PMCID: PMC2175921.